Unlock this StockReport nowClick to Unlock

Realm Therapeutics

RLM 8.25p 0.0  0.0%
17/10/18 2.00k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 3 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary

FINANCIAL BRIEF: For the six months ended 30 June 2018, Realm Therapeutics PLC revenues decreased from $619K to $0K. Net loss increased from $3.9M to $10.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses increase from $3M to $7.4M (expense), General and administrative expenses increase from $1.6M to $3.5M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
E-
E-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2018
31st Dec 2019

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for Realm Therapeutics
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Equity Development Emma Ulker , N+1 Singer Chris Glasper ,

Profile Summary

Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.

Directors: John Martin (CEO) 49, Marella Thorell (SEC) 49, Charles Spicer (NEC) 50, Ivan Gergel (NED) 57, Balkrishan Gill (NED) 51, Sanford Zweifach (NED) 61, Joseph Birkett (NID) 67,

No. of Employees: 15 No. of Shareholders: n/a


Last Annual December 31st, 2017
Last Interim June 30th, 2018
Incorporated April 21, 2006
Public Since June 30, 2006
Shares in Issue 116,561,917
Free Float 91.0m (78.1%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

RLM Share Price Performance RLMQuote
8.25p
0.0  0.0%
Traded 1:00am · Minimum 15 min delayed · NMS: 2.00k

Latest RLM News Announcements (delayed)

Upcoming RLM Events

Recent ↓
Wednesday 6th June, 2018 (estimate)
Realm Therapeutics PLC Annual Shareholders Meeting
Friday 23rd March, 2018 (estimate)
Full Year 2017 Realm Therapeutics PLC Earnings Release
Friday 22nd September, 2017
Realm Therapeutics PLC Secondary Public Offering Pricing
Tuesday 6th June, 2017
Realm Therapeutics PLC Annual Shareholders Meeting
Thursday 23rd March, 2017
Full Year 2016 Realm Therapeutics PLC Earnings Call
Thursday 23rd March, 2017
Full Year 2016 Realm Therapeutics PLC Earnings Release
Thursday 6th October, 2016
PuriCore PLC Ordinary Shareholders Meeting
Tuesday 20th September, 2016
Half Year 2016 PuriCore PLC Earnings Release
Thursday 16th June, 2016
PuriCore PLC Annual Shareholders Meeting
Thursday 24th March, 2016
Full Year 2015 PuriCore PLC Earnings Release


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.


Should you buy RLM

Access RLM Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis